BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Boehringer Ingelheim GmbH 

Binger Str. 173

Ingelheim    D-55126  Germany
Phone: 49-6132-77-0 Fax: 49-6132-72-0


SEARCH JOBS


Industry
Suppliers






 Company News
Boehringer Ingelheim GmbH Release: Better Outcome in Case of Major Bleed for Patients Taking the Anticoagulant Pradaxa® Compared to Warfarin 10/7/2013 10:01:24 AM    More...
Boehringer Ingelheim GmbH Release: Data Presented at EASD Support Safety Profile of Trajenta® (Linagliptin) In Broad Range of Adults With Type 2 Diabetes 9/24/2013 6:38:50 AM    More...
Boehringer Ingelheim GmbH's Respimat Inhaler Meets Safety Goal in Study 9/3/2013 8:08:54 AM    More...
Swedish Orphan Biovitrum Gets FDA Approval to Manufacture Substance for Kineret® With Partner Boehringer Ingelheim Corporation 6/11/2013 9:48:34 AM    More...
Boehringer Ingelheim GmbH and Eli Lilly and Company (LLY) Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions® 6/11/2013 6:53:52 AM    More...
Boehringer Ingelheim GmbH Release: FDA and FDA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients With Atrial Fibrillation 11/5/2012 9:55:43 AM    More...
FDA: No Increased Bleeding Risk for Boehringer Ingelheim GmbH's Pradaxa 11/2/2012 2:47:05 PM    More...
Wealth of Worldwide Evidence on Boehringer Ingelheim GmbH's Pradaxa® Including First Clinical Data on Long-Term Efficacy and Safety of a Novel Oral Anticoagulant to be Presented at American Heart Association Scientific Sessions 10/31/2012 8:26:16 AM    More...
Boehringer Ingelheim GmbH Release: Asian Populations With Atrial Fibrillation (AF) Benefit From Better Stroke Prevention With Pradaxa® (dabigatran etexilate) Compared to Warfarin 9/12/2012 10:20:42 AM    More...
Boehringer Ingelheim GmbH Release: AF Patients Who Require Surgery Benefit From a Shorter Treatment Interruption on Dabigatran Etexilate (Pradaxa®) Compared to Warfarin 6/18/2012 10:21:41 AM    More...
12345678910...

//-->